Proposed explanations include: Tissue retention of peptide or active metabolites Persistent activation of signaling cascades beyond peptide clearance Potential for active metabolites with prolonged tissue residence Excretion Pathways Limited data on elimination routes indicates: Likely renal excretion of peptide fragments based on molecular weight and water solubility Potential hepatic contribution to metabolite clearance No evidence of accumulation in chronic dosing studies in rats and monkeys Degradation products eliminated without evidence of toxic metabolite formation The dramatic disconnect between three-minute plasma half-life and prolonged metabolic effects remains one of the most intriguing and poorly understood aspects of AOD-9604 pharmacology, requiring further mechanistic investigation
Doctors might adjust this based on how the patient responds and their health
After treatment, patients are free to leave and resume normal activities immediately
In contrast, the effect of topical GSCPs was similar to that of the control
Given its regenerative properties and favorable safety profile, AOD9604 holds promise as a novel therapeutic agent for OA, especially when used in conjunction with established treatments like HA [1]
Shots are suggested for those with a Vitamin B12 deficiency, like those with absorption issues or who cant get enough from food
